XM no presta servicios a los residentes de Estados Unidos de América.

XM no presta servicios a los residentes de Estados Unidos de América.
R
R

Roche

Noticias

Reuters - Hace 11 horas

Roche’S Phase III Starglo Study Demonstrates Columvi Significantly Extends Survival In People

BRIEF-Roche’S Phase III Starglo Study Demonstrates Columvi Significantly Extends Survival In People June 15 (Reuters) - Roche Holding AG ROG.S : ROCHE’S PHASE III STARGLO STUDY DEMONSTRATES COLUMVI SIGNIFICANTLY EXTENDS SURVIVAL IN PEOPLE WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA STUDY MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVA
R
Reuters - Hace 1 día

Tempus AI shares jump 8% in strong Nasdaq debut as US IPO market thaws

UPDATE 2-Tempus AI shares jump 8% in strong Nasdaq debut as US IPO market thaws Adds background in paragraphs 6-10 June 14 (Reuters) - Shares of SoftBank Group-backed 9984.T Tempus AI TEM.O rose 8.1% in their debut on the Nasdaq on Friday, giving the artificial intelligence-based genetic testing company a valuation of $6.6 billion. The company is among the several AI-focused firms that have garnered investors' interest, thanks to the popularity of OpenAI's viral chatbot ChatGPT.
A
G
R
T
Reuters - Hace 2 días

AB Dynamics, Etteplan, Wise

EUROPE RESEARCH ROUNDUP-AB Dynamics, Etteplan, Wise June 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AB Dynamics, Etteplan and Wise, on Friday. HIGHLIGHTS * AB Dynamics Plc ABDP.L : Berenberg re-initiates coverage With Buy rating; PT 2,620p * Crest Nicholson CRST.L : Barclays cuts target price to 230p from 258p * Etteplan Oyj ETTE.HE : Evli Research raises to buy from hold * Halma HLMA.L : Barclays raises target price to 284
B
C
E
H
H
J
L
O
O
P
R
S
S
T
U
V
V
Z
H
A
R
Reuters - Hace 2 días

AbbVie inks immune disorder drug licensing deal with China's FutureGen

AbbVie inks immune disorder drug licensing deal with China's FutureGen June 13 (Reuters) - U.S. drugmaker AbbVie ABBV.N will develop and commercialize an experimental treatment for inflammatory bowel disease (IBD) from China's FutureGen Biopharmaceutical under a licensing agreement, the companies said on Thursday. WHY IT'S IMPORTANT AbbVie has been counting on its newer immunology medicines to help make up for declining sales of blockbuster arthritis drug Humira following the entry of biosimilar
R
Reuters - Hace 5 días

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V
Reuters - Hace 5 días

Roche: European Commission Approves Alecensa For People With Alk-Positive Early-Stage Lung Cancer

BRIEF-Roche: European Commission Approves Alecensa For People With Alk-Positive Early-Stage Lung Cancer June 11 (Reuters) - Roche Holding AG ROG.S : EUROPEAN COMMISSION APPROVES ROCHE'S ALECENSA AS FIRST AND ONLY TARGETED ADJUVANT TREATMENT FOR PEOPLE WITH ALK-POSITIVE EARLY-STAGE LUNG CANCER Source text: [ https://bit.ly/3ySrJwS ] Further company
R
Reuters - Hace 5 días

Japan's Nikkei rises on US stocks, heavyweight chip shares

Japan's Nikkei rises on US stocks, heavyweight chip shares By Brigid Riley TOKYO, June 11 (Reuters) - Japan's Nikkei share average rose during morning trade on Tuesday as investors cheered record closing highs on Wall Street , which prompted a jump in heavyweight domestic semiconductor stocks. The Nikkei .N225 was up 0.3% at 39,155.16 by the midday break, after touching a three-week high of 39,336.66 earlier in the session.
R
U
J
U
Reuters - Hace 6 días

Alzpath Announces Licensing Agreement With Roche For Use Of Alzpath's Proprietary Ptau217 Antibody In Blood Test To Diagnose Alzheimer's Disease

BRIEF-Alzpath Announces Licensing Agreement With Roche For Use Of Alzpath's Proprietary Ptau217 Antibody In Blood Test To Diagnose Alzheimer's Disease June 10 (Reuters) - Roche Holding AG ROG.S : ALZPATH ANNOUNCES LICENSING AGREEMENT WITH ROCHE FOR USE OF ALZPATH'S PROPRIETARY PTAU217 ANTIBODY IN BLOOD TEST TO DIAGNOSE ALZHEIMER'S DISEASE Source te
R
Reuters - Hace 6 días

Swiss stocks - Factors to watch on June 10

Swiss stocks - Factors to watch on June 10 ZURICH/GDANSK, June 10(Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday: COMPANY STATEMENTS * Roche ROG.S - European Commission approves Roche’s Alecensa * Barry Callebaut AG BARN.S - Places New EUR 700 Mln Denominated Bond * Dormakaba Holding AG DOKA.S - To Divest Its Sub-Saharan African Business * Metall Zug AG METN.S , METN.S - Announces Start of JV ANALYSTS' VIEWS BARRY CALLEBAUT AG BARN.S - BERENBERG RAISES TARG
N
N
R
S
Reuters - Hace 6 días

Roche Says FDA Granted Emergency Use Authorization For Cobas Liat Sars-Cov-2, Influenza A/B & Rsv Nucleic Acid Test

BRIEF-Roche Says FDA Granted Emergency Use Authorization For Cobas Liat Sars-Cov-2, Influenza A/B & Rsv Nucleic Acid Test June 10 (Reuters) - ROCHE HOLDING AG ROG.S : ROCHE FOUR-IN-ONE MOLECULAR TEST FOR SARS-COV-2, INFLUENZA A/B VIRUSES AND RSV RECEIVES U.S. FDA EMERGENCY USE AUTHORIZATION TEST USES REQUIRES ONLY A SINGLE NASAL-SWAB SAMPLE FDA HAS
R
Reuters - Hace 6 días

European Commission approves Roche’s Alecensa as targeted adjuvant treatment for alk-positive early-stage lung cancer

BRIEF-European Commission approves Roche’s Alecensa as targeted adjuvant treatment for alk-positive early-stage lung cancer June 10 (Reuters) - ROCHE HOLDING AG ROG.S : EUROPEAN COMMISSION APPROVES ROCHE’S ALECENSA AS THE FIRST AND ONLY TARGETED ADJUVANT TREATMENT FOR PEOPLE WITH ALK-POSITIVE EARLY-STAGE LUNG CANCER ROCHE HOLDING AG - ALECENSA
R
Reuters - Hace 1 semana

Roche Confirms Efficacy Of Evrysdi In Children With Type 1 Spinal Muscular Atrophy

BRIEF-Roche Confirms Efficacy Of Evrysdi In Children With Type 1 Spinal Muscular Atrophy June 7 (Reuters) - ROCHE HOLDING AG ROG.S : ANNOUNCED TODAY NEW FIVE-YEAR DATA CONFIRMING SUSTAINED EFFICACY AND SAFETY PROFILE OF EVRYSDI IN CHILDREN WITH TYPE 1 SPINAL MUSCULAR ATROPHY AFTER FIVE YEARS OF TREATMENT, 91% OF CHILDREN WERE ALIVE - WITHOUT TREATM
R
Reuters - Hace 1 semana

Novartis, Roche unit and others face Italy antitrust probe over eye drug

UPDATE 3-Novartis, Roche unit and others face Italy antitrust probe over eye drug Adds Biogen comment in last paragraph ROME, June 6 (Reuters) - Italy's antitrust regulator said on Thursday it had launched an investigation into pharmaceutical companies including Novartis NOVN.S and Roche-controlled ROG.S Genentech for having potentially restricted competition in the sale of an eye drug.
B
N
R
Reuters - Hace 1 semana

Novartis and others face Italy antitrust probe over eye drug

Novartis and others face Italy antitrust probe over eye drug ROME, June 6 (Reuters) - Italy's antitrust regulator said on Thursday it had launched a probe into several pharmaceutical companies, including Novartis NOVN.S , for having potentially restricted competition in the sale of a drug for eye conditions. Samsung Bioepis, Biogen, Genentech and Novartis, and some of their Italian, Dutch and UK units, allegedly coordinated their commercial strategies to delay the launch in Italy of Byooviz, a d
B
N
R
Reuters - Hace 2 semanas

SoftBank-backed Tempus AI seeks up to $6.1 bln valuation in US IPO

UPDATE 2-SoftBank-backed Tempus AI seeks up to $6.1 bln valuation in US IPO Adds background and details on competitors, customers and funding in paragraphs 4-10 June 5 (Reuters) - Tempus AI, backed by Japanese tech investment firm SoftBank Group 9984.T , is targeting a valuation of up to $6.10 billion for its U.S. initial public offering, nearly three years after the genetics-testing company laid the ground for its listing.
A
G
G
R
V
Reuters - Hace 2 semanas

Weight-loss drug developers line up to tap market worth $150 billion

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion Updates estimate for obesity drug market size June 4 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the e arly 2030s . But there are several other drug developers aiming to join the bandwagon.
A
O
P
R
Reuters - Hace 2 semanas

Weight-loss drug developers line up to tap market worth $150 billion

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion Updates estimate for obesity drug market size June 4 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the e arly 2030s . But there are several other drug developers aiming to join the bandwagon.
A
O
P
R
Reuters - Hace 2 semanas

Astra's Enhertu breast cancer trial shows 'unprecedented' results

UPDATE 1-Astra's Enhertu breast cancer trial shows 'unprecedented' results Adds analyst comment in paragraph 8 By Deena Beasley June 2 (Reuters) - AstraZeneca AZN.L and Daiichi Sankyo's 4568.T Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.
A
R
Reuters - Hace 2 semanas

Astra's Enhertu delays breast cancer in patients with low HER2 levels

Astra's Enhertu delays breast cancer in patients with low HER2 levels By Deena Beasley June 2 (Reuters) - AstraZeneca AZN.L and Daiichi Sankyo's 4568.T Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.
A
R
Reuters - Hace 2 semanas

Currys, Ovhcloud, Whitbread

EUROPE RESEARCH ROUNDUP-Currys, Ovhcloud, Whitbread May 30 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Currys, Ovhcloud and Whitbread, on Thursday. HIGHLIGHTS * Anglo American AAL.L : Jefferies cuts to hold from buy * Currys Plc CURY.L : Berenberg raises to buy from hold * Ovhcloud OVH.PA : Stifel cuts to hold from buy * Solvay SOLB.BR : Morgan Stanley raises to equal weight from underweight * Whitbread WTB.L : Berenberg cuts t
A
A
B
B
E
F
G
K
L
L
M
M
N
P
R
S
W
W
H
A
A
A
M

Condiciones

Activos populares

Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.

Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.

Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.

Advertencia de riesgo: Su capital está en riesgo. Los productos apalancados pueden no ser adecuados para todos. Por favor, tenga en cuenta nuestra Declaración de riesgos.